Triple-negative breast cancer (TNBC) is a unique subgroup defined by a lack expression of ER (estrogen receptor),PR(progesterone receptor) and HER2 (human epidermal growth factor receptor 2),which has distinctly biological,clinical and pathological characteristics.This subgroup has close relationship with basal-like and BRCA1 (breast cancer susceptibility gene-1) breast cancers.Since endocrine and HER2-targered therapy can not be applied,chemotherapy is the major mean of therapy.Some studies show that TNBC is sensitive to taxol,platinum and anthracycline-based chemotherapy.Furthermore,targeted therapy to EGFR (epidermal growth factor receptor),c-kit (stem cell factor receptor) and PARP (poly ADP-ribose polymerase) inhibitor may show better anticancer activity.We will review this subgroup of breast cancer as the following three aspects,biological characteristics,clinicopathology characteristics and therapy strategy.